# CSF1R Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- CSF1R is a class III receptor tyrosine kinase crucial for mononuclear phagocyte system development and function, acting as the primary receptor for CSF1 and IL-34, and is a key regulator of tumor-associated macrophages (TAMs).
- Germline heterozygous mutations in CSF1R lead to adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a neurodegenerative disorder characterized by microglial dysfunction and white matter abnormalities.
- Somatic mutations in CSF1R, particularly at the Y561 hotspot, are implicated in hematological malignancies like chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), driving constitutive kinase activation.
- Pexidartinib (PLX3397) is an FDA-approved ATP-competitive small-molecule inhibitor of CSF1R, primarily used for tenosynovial giant cell tumor (TGCT), with ongoing investigations for its use in combination therapies for solid tumors and glioblastoma.
- CSF1R signaling is exploited by various pathogens, including HCMV, HIV, and *Mycobacterium tuberculosis*, to promote host cell survival and immune evasion, making it a target for host-directed antimicrobial therapies.
- The CSF1R signaling pathway is tightly regulated by phosphorylation events (e.g., Y561, Y809, Y921), ubiquitination (CBL-mediated), and ectodomain shedding (ADAM17), with dysregulation contributing to both inherited neurological diseases and cancer progression.

---

## Executive Summary & Key Metadata

The colony-stimulating factor 1 receptor (CSF1R), also known as FMS proto-oncogene, is a class III receptor tyrosine kinase (RTK) that governs the survival, proliferation, differentiation, and chemotaxis of cells of the mononuclear phagocyte system, including monocytes, macrophages, and osteoclasts. It is the principal receptor for two ligands: colony-stimulating factor 1 (CSF1, also called M-CSF) and interleukin-34 (IL-34). Beyond its physiological role in innate immunity and bone homeostasis, CSF1R is a central node in tumor-associated macrophage (TAM) biology, making it a high-priority therapeutic target in oncology. Germline mutations in CSF1R cause adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), while somatic mutations are implicated in several hematological malignancies.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | CSF1R |
| UniProt Accession | P07333 |
| Representative PDB ID | 4R7I (extracellular domain with CSF1), 3KRL (kinase domain) |
| Chromosomal Locus | 5q32 (GRCh38: chr5:150,053,295–150,097,507) |
| Primary Molecular Function | Receptor tyrosine kinase; binds CSF1 and IL-34; activates PI3K/AKT, RAS/MAPK, and JAK/STAT pathways |
| Disease & Pathology Associations | ALSP (autosomal dominant leukodystrophy); chronic myelomonocytic leukemia (CMML); acute myeloid leukemia (AML); tenosynovial giant cell tumor (TGCT); diffuse-type giant cell tumor; breast, ovarian, and pancreatic cancer (via TAM regulation) |
| Gene Size | ~44 kb genomic DNA; 18 exons (coding) |
| Protein Length | 972 amino acids (isoform 1); 953 amino acids (isoform 2) |
| Post-translational Modifications | N-linked glycosylation (N323, N382, N390); ubiquitination; phosphorylation (Y561, Y699, Y708, Y723, Y809, Y921, Y969) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Gene Architecture

The CSF1R gene is located on the long arm of chromosome 5 at band q32 (5q32). The locus spans approximately 44 kilobases (kb) of genomic DNA on the minus strand (GRCh38/hg38: chr5:150,053,295–150,097,507). The gene is oriented in a head-to-tail arrangement with its neighboring gene, PDGFRB (platelet-derived growth factor receptor beta), which lies approximately 500 bp upstream. This genomic proximity is evolutionarily conserved and reflects a shared ancestral duplication event that gave rise to the class III RTK family. The two genes share regulatory elements, including a bidirectional promoter region, and are frequently co-deleted in the 5q- syndrome, a subtype of myelodysplastic syndrome (MDS).

The CSF1R transcription unit comprises 22 exons, of which 18 are protein-coding. Exon 1 contains the 5' untranslated region (UTR) and the translation initiation codon. Exons 2–5 encode the N-terminal immunoglobulin (Ig)-like domains (D1–D3). Exon 6 encodes the fourth Ig-like domain (D4). Exons 7–11 encode the fifth Ig-like domain (D5) and the juxtamembrane (JM) region. Exons 12–14 encode the intracellular tyrosine kinase domain split into N-lobe and C-lobe. Exons 15–18 encode the kinase insert domain and the C-terminal tail. The 3' UTR is unusually long (~2.5 kb) and contains multiple AU-rich elements (AREs) that mediate mRNA instability in response to cellular signals.

### 1.2 Promoter Architecture and Transcriptional Regulation

The CSF1R promoter is a TATA-less, GC-rich promoter containing multiple Sp1 (specificity protein 1) binding sites. The core promoter spans approximately 200 bp upstream of the transcription start site (TSS). Key regulatory elements include:

- **Sp1/Sp3 binding sites**: Essential for basal transcription in myeloid cells. Sp1 occupancy is constitutive, while Sp3 acts as a repressor in non-myeloid cells.
- **PU.1 (Spi1) binding site**: Located at −55 to −45 bp relative to the TSS. PU.1 is a master myeloid transcription factor and is absolutely required for CSF1R expression in macrophages. PU.1 cooperates with C/EBPα (CCAAT/enhancer-binding protein alpha) to drive high-level expression.
- **RUNX1 (AML1) binding site**: Located in the first intron. RUNX1 binding is required for definitive hematopoiesis and CSF1R expression in hematopoietic stem cells.
- **E-box elements**: Bound by basic helix-loop-helix (bHLH) factors such as TAL1/SCL, which regulate expression in early myeloid progenitors.
- **Enhancer elements**: A distal enhancer located ~10 kb upstream (at chr5:150,043,000–150,045,000) contains binding sites for PU.1, C/EBPα, and AP-1. This enhancer is marked by H3K27ac in macrophages and is silenced in non-hematopoietic tissues via DNA methylation.

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of CSF1R generates multiple transcript variants. The two principal protein-coding isoforms are:

- **Isoform 1 (972 aa)**: The canonical full-length receptor. Encoded by all 18 coding exons. This is the predominant isoform in macrophages and osteoclasts.
- **Isoform 2 (953 aa)**: Lacks exon 6 (encoding Ig-like domain D4). This isoform is expressed in trophoblast cells and certain cancer cell lines. The deletion of D4 does not abrogate ligand binding but alters receptor dimerization kinetics.

Additionally, a soluble form of CSF1R (sCSF1R) is generated by alternative splicing that introduces a premature stop codon in exon 12, producing a truncated protein lacking the transmembrane and kinase domains. sCSF1R is secreted into the plasma and acts as a decoy receptor, sequestering CSF1 and IL-34. Elevated sCSF1R levels are observed in inflammatory conditions and certain cancers.

A rare splice variant retaining intron 10 has been reported in acute myeloid leukemia (AML) cell lines. This variant encodes a constitutively active receptor due to a frameshift that removes the juxtamembrane autoinhibitory domain.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Topology

CSF1R is a single-pass type I transmembrane glycoprotein of 972 amino acids. The mature protein is organized into three principal segments: a large extracellular domain (ECD, residues 1–512), a single hydrophobic transmembrane helix (TM, residues 513–535), and an intracellular region (residues 536–972) comprising the juxtamembrane (JM) domain, the split tyrosine kinase domain, and a C-terminal tail.

### 2.2 Extracellular Domain (ECD)

The ECD consists of five immunoglobulin (Ig)-like domains, designated D1–D5 from the N-terminus. Each Ig domain adopts a β-sandwich fold composed of two antiparallel β-sheets. The structural organization is as follows:

- **D1 (residues 1–110)**: N-terminal Ig-like domain. Contains the primary binding site for CSF1. Structural studies (PDB: 4R7I) show that D1 forms a hydrophobic interface with CSF1, burying ~1,500 Ų of solvent-accessible surface area.
- **D2 (residues 111–210)**: Ig-like domain. Participates in ligand-induced receptor dimerization by forming homotypic contacts with D2 of the opposing receptor monomer.
- **D3 (residues 211–310)**: Ig-like domain. Contains the binding site for IL-34. The IL-34 binding interface is distinct from the CSF1 interface but partially overlaps, explaining the competitive binding of the two ligands.
- **D4 (residues 311–410)**: Ig-like domain. This domain is dispensable for ligand binding but contributes to the overall rigidity of the ECD. Its deletion (isoform 2) alters the angle between D3 and D5.
- **D5 (residues 411–512)**: Membrane-proximal Ig-like domain. Contains a flexible hinge region that allows the ECD to adopt an extended conformation. D5 also contains the proteolytic cleavage site for ADAM17 (TACE), which mediates ectodomain shedding.

The ECD is heavily N-glycosylated at residues N323, N382, and N390. Glycosylation is required for proper folding and trafficking to the cell surface. The carbohydrate moieties also shield the receptor from proteolytic degradation.

### 2.3 Transmembrane and Juxtamembrane Domains

The transmembrane helix (residues 513–535) is a canonical hydrophobic α-helix with a GxxxG dimerization motif. This motif facilitates ligand-independent receptor dimerization at high local concentrations in the plasma membrane.

The juxtamembrane domain (JM, residues 536–581) is a critical autoinhibitory element. In the inactive state, the JM domain folds into the kinase domain and forms a hydrophobic interaction with the N-lobe of the kinase, stabilizing the kinase in an open, inactive conformation. Specifically, residues W550, W553, and Y561 insert into a hydrophobic pocket between the N-lobe and C-lobe of the kinase domain. Phosphorylation of Y561 disrupts this autoinhibitory interaction, leading to kinase activation.

### 2.4 Intracellular Kinase Domain

The kinase domain (residues 582–920) adopts the canonical bilobal protein kinase fold:

- **N-lobe (residues 582–700)**: Composed of a five-stranded β-sheet and the αC-helix. The N-lobe contains the phosphate-binding loop (P-loop, residues 595–605) that coordinates ATP.
- **C-lobe (residues 701–920)**: Predominantly α-helical. Contains the catalytic loop (HRDLAARN, residues 778–785), the activation loop (A-loop, residues 809–835), and the DFG motif (D811, F812, G813).

The kinase insert domain (residues 740–760) is a unique feature of class III RTKs. It protrudes from the C-lobe and contains phosphorylation sites (Y744, Y749) that serve as docking sites for downstream signaling proteins such as GRB2 and PI3K.

The activation loop (A-loop) is the primary regulatory switch. In the inactive state, the A-loop adopts a conformation that blocks the substrate-binding cleft. Phosphorylation of Y809 and Y921 within the A-loop induces a conformational change that opens the active site and stabilizes the active kinase conformation.

### 2.5 C-Terminal Tail

The C-terminal tail (residues 921–972) contains a conserved tyrosine residue (Y969) that, when phosphorylated, serves as a docking site for the E3 ubiquitin ligase CBL. CBL-mediated ubiquitination targets the receptor for endocytosis and lysosomal degradation, providing a negative feedback mechanism.

### 2.6 Structural Dynamics and Allostery

Recent cryo-electron microscopy (cryo-EM) studies of the full-length CSF1R in complex with CSF1 (PDB: 6R0A) have revealed that ligand binding induces a large conformational rearrangement. In the unliganded state, the ECD adopts a bent, autoinhibited conformation where D1–D3 fold back toward D4–D5. Ligand binding to D1 and D3 stabilizes an extended conformation, bringing the two receptor monomers into close proximity. This ligand-induced dimerization is further stabilized by D2–D2 homotypic contacts. The resulting conformational change is transmitted across the membrane through the TM helix, releasing the JM domain from the kinase domain and initiating trans-autophosphorylation.

> **Interactive 3D Protein Visualizer: Load CSF1R (PDB: true)**
> [Interactive 3D Protein Visualizer: Load CSF1R (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P07333)
> This tool loads the experimentally determined structure of the CSF1R extracellular domain in complex with CSF1 (PDB: 4R7I) and the kinase domain (PDB: 3KRL). Users can toggle between domains, visualize phosphorylation sites, and measure atomic distances.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Ligand Binding and Receptor Activation

CSF1R is activated by two structurally unrelated ligands: CSF1 (a homodimeric glycoprotein of ~45–90 kDa) and IL-34 (a homodimeric protein of ~39 kDa). Both ligands bind to the ECD with high affinity (Kd ≈ 10–100 pM for CSF1; Kd ≈ 100–500 pM for IL-34). Despite their lack of sequence homology, both ligands engage D1 and D3 of the receptor. CSF1 is the primary ligand in most tissues, while IL-34 is expressed predominantly in the brain, skin, and reproductive organs.

Ligand binding induces receptor dimerization, which brings the two intracellular kinase domains into close proximity. This proximity enables trans-autophosphorylation of key tyrosine residues. The initial phosphorylation event occurs at Y561 in the JM domain, which releases the autoinhibitory interaction. Subsequent phosphorylation of Y699, Y708, and Y723 in the kinase insert domain and Y809/Y921 in the activation loop fully activates the kinase.

### 3.2 Downstream Signaling Cascades

Once fully activated, phosphorylated tyrosine residues on CSF1R serve as docking sites for Src homology 2 (SH2) domain-containing proteins. The principal downstream pathways are:

#### 3.2.1 PI3K/AKT Pathway
Phosphorylated Y723 recruits the p85 regulatory subunit of phosphoinositide 3-kinase (PI3K). PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 recruits AKT to the plasma membrane, where it is phosphorylated and activated by PDK1 and mTORC2. AKT promotes cell survival by phosphorylating and inactivating pro-apoptotic proteins (BAD, FOXO) and activating pro-survival transcription factors (NF-κB). In macrophages, AKT signaling also drives the expression of anti-inflammatory cytokines such as IL-10.

#### 3.2.2 RAS/MAPK Pathway
Phosphorylated Y699 and Y708 recruit the adaptor protein GRB2, which is constitutively bound to the guanine nucleotide exchange factor SOS. SOS activates RAS by promoting GDP→GTP exchange. GTP-bound RAS activates the RAF/MEK/ERK kinase cascade. ERK translocates to the nucleus and phosphorylates transcription factors such as ELK1 and c-FOS, driving cell proliferation and differentiation. In osteoclast precursors, sustained ERK signaling is required for RANKL-induced osteoclast differentiation.

#### 3.2.3 JAK/STAT Pathway
CSF1R associates with JAK1 and JAK2 kinases. Upon receptor activation, JAKs phosphorylate STAT1, STAT3, and STAT5. Phosphorylated STATs dimerize and translocate to the nucleus, where they regulate genes involved in inflammation and immune suppression. STAT3 activation in TAMs promotes an M2-like immunosuppressive phenotype.

#### 3.2.4 SRC Family Kinases
The JM domain, once phosphorylated at Y561, recruits SRC family kinases (SFKs) such as SRC, FYN, and YES. SFKs phosphorylate additional substrates, including the actin cytoskeleton regulator WASP, promoting cell migration and membrane ruffling. SFK signaling is essential for CSF1-induced macrophage chemotaxis.

### 3.3 Negative Regulation and Receptor Turnover

CSF1R signaling is tightly regulated by multiple mechanisms:

- **Dephosphorylation**: Protein tyrosine phosphatases (PTPs), including SHP-1 and PTP1B, dephosphorylate the receptor and terminate signaling. SHP-1 binds to the immunoreceptor tyrosine-based inhibition motif (ITIM)-like sequence in the JM domain.
- **Ubiquitination and Degradation**: The E3 ubiquitin ligase CBL binds to phosphorylated Y969 and ubiquitinates the receptor. Ubiquitinated CSF1R is internalized via clathrin-mediated endocytosis and sorted to lysosomes for degradation. This process is accelerated by the adaptor protein CIN85.
- **Ectodomain Shedding**: ADAM17 cleaves the ECD at the D5 domain, releasing sCSF1R into the extracellular space. sCSF1R acts as a decoy receptor, reducing local ligand concentration.
- **Transcriptional Regulation**: CSF1R mRNA is destabilized by AU-rich elements in the 3' UTR. The RNA-binding protein tristetraprolin (TTP) binds to these elements and promotes mRNA decay, providing a rapid shut-off mechanism.

### 3.4 Protein-Protein Interaction Network

The CSF1R interactome includes over 50 confirmed binding partners (BioGRID: 87 interactions). Key nodes include:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| GRB2 | SH2 domain binding (Y699) | Activates RAS/MAPK pathway |
| PIK3R1 (p85) | SH2 domain binding (Y723) | Activates PI3K/AKT pathway |
| CBL | SH2 domain binding (Y969) | Ubiquitination and degradation |
| SRC | SH2 domain binding (Y561) | Cytoskeletal remodeling, migration |
| JAK1/JAK2 | Constitutive association | STAT activation |
| SHP-1 | SH2 domain binding (JM) | Negative regulation |
| SHC1 | SH2 domain binding | RAS activation |
| PLCγ | SH2 domain binding | Calcium signaling |
| CIN85 | Proline-rich motif | Endocytosis |
| SOCS1 | Kinase domain | Negative regulation |

### 3.5 Physiological Functions

CSF1R signaling is indispensable for:

- **Monocyte/Macrophage Development**: CSF1R is expressed on committed myeloid progenitors. CSF1 signaling drives their differentiation into monocytes and tissue-resident macrophages. Mice lacking CSF1R (Csf1r−/−) have severe monocytopenia and osteopetrosis.
- **Osteoclastogenesis**: CSF1R is required for the differentiation of osteoclast precursors into multinucleated bone-resorbing osteoclasts. CSF1 signaling induces RANK expression, priming cells for RANKL stimulation.
- **Microglial Maintenance**: In the central nervous system, CSF1R signaling via IL-34 is essential for the development and maintenance of microglia. CSF1R inhibition leads to rapid microglial depletion.
- **Langerhans Cell Homeostasis**: CSF1R signaling maintains epidermal Langerhans cells, a subset of dendritic cells.
- **Mammary Gland Development**: CSF1R is expressed on mammary epithelial cells during pregnancy and lactation, where it regulates ductal branching and milk production.

```mermaid
sequenceDiagram
    participant L as "CSF1/IL-34"
    participant R as "CSF1R (inactive)"
    participant R' as CSF1R (active)
    participant P as "PI3K"
    participant A as "AKT"
    participant M as "MAPK/ERK"
    participant S as "STAT3"
    participant N as "Nucleus"
    L->>R: Ligand binding
    R->>R': Dimerization & trans-autophosphorylation
    R'->>P: Recruits p85 (Y723)
    R'->>M: Recruits GRB2/SOS (Y699)
    R'->>S: Recruits JAK/STAT
    P->>A: PIP3 generation
    A->>N: Survival genes (BCL2, MCL1)
    M->>N: Proliferation genes (FOS, MYC)
    S->>N: Immune suppression genes (IL10, VEGFA)
    R'->>R: CBL-mediated ubiquitination & degradation
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations: Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)

ALSP (OMIM #221820) is an autosomal dominant neurodegenerative disorder caused by heterozygous missense mutations in CSF1R. The disease is characterized by progressive cognitive decline, psychiatric symptoms, motor dysfunction, and white matter abnormalities on MRI. Onset typically occurs between 40 and 60 years of age, with a mean survival of 6–7 years after diagnosis.

The pathogenic mechanism involves haploinsufficiency and dominant-negative effects. Mutant CSF1R proteins are misfolded and retained in the endoplasmic reticulum (ER), leading to ER stress and reduced cell-surface receptor levels. The loss of CSF1R signaling in microglia results in impaired microglial function, axonal spheroids, and demyelination.

**Hotspot mutations in ALSP:**

| **Mutation** | **Domain** | **Pathogenic Mechanism** | **ClinVar Classification** |
|---|---|---|---|
| p.Ile332Thr (c.995T>C) | D4 (ECD) | Impaired folding, ER retention | Pathogenic |
| p.Arg504Trp (c.1510C>T) | D5 (ECD) | Impaired ligand binding | Pathogenic |
| p.Leu540Pro (c.1619T>C) | JM domain | Disrupts autoinhibitory conformation | Pathogenic |
| p.Trp550Arg (c.1648T>C) | JM domain | Destabilizes JM-kinase interaction | Pathogenic |
| p.Trp553Arg (c.1657T>C) | JM domain | Destabilizes JM-kinase interaction | Pathogenic |
| p.Tyr561Cys (c.1682A>G) | JM domain | Alters phosphorylation site | Pathogenic |
| p.Glu633Lys (c.1897G>A) | Kinase N-lobe | Impaired ATP binding | Pathogenic |
| p.Leu781Pro (c.2342T>C) | Kinase C-lobe | Destabilizes catalytic loop | Pathogenic |
| p.Arg782His (c.2345G>A) | Kinase C-lobe | Disrupts catalytic HRD motif | Pathogenic |
| p.Asp811Tyr (c.2431G>T) | DFG motif | Disrupts ATP coordination | Pathogenic |
| p.Pro878Leu (c.2633C>T) | Kinase C-lobe | Impaired kinase activity | Pathogenic |

### 4.2 Somatic Mutations in Hematological Malignancies

Somatic CSF1R mutations are less common than mutations in other RTKs but are recurrently observed in:

- **Chronic Myelomonocytic Leukemia (CMML)**: Mutations are found in ~5–10% of CMML cases. The most frequent mutation is p.Tyr561Cys (Y561C), which disrupts the JM autoinhibitory domain, leading to constitutive kinase activation. Other recurrent mutations include p.Asp802Val (D802V) and p.Met835Thr (M835T) in the activation loop.
- **Acute Myeloid Leukemia (AML)**: CSF1R mutations are found in ~2–3% of AML cases. These mutations often co-occur with FLT3-ITD or NPM1 mutations. The p.Leu301Ser (L301S) mutation in D3 enhances ligand-independent dimerization.
- **Myelodysplastic Syndrome (MDS)**: The 5q- syndrome involves deletion of the entire CSF1R locus. Haploinsufficiency of CSF1R contributes to the dysplastic phenotype.

### 4.3 Mutations in Tenosynovial Giant Cell Tumor (TGCT)

TGCT (also called pigmented villonodular synovitis) is a locally aggressive neoplasm of the synovium. Approximately 60% of TGCT cases harbor a recurrent chromosomal translocation t(1;2)(p13;q37) that fuses the CSF1 gene to the COL6A3 promoter. This translocation leads to overexpression of CSF1, which acts as a paracrine growth factor, recruiting CSF1R-expressing macrophages that constitute the bulk of the tumor. A smaller subset of TGCTs harbors activating CSF1R mutations, including p.Tyr561Asp (Y561D).

### 4.4 Mutations in Solid Tumors

CSF1R mutations in solid tumors are rare but have been reported in:

- **Melanoma**: p.Arg504Cys (R504C) in D5, which impairs ligand binding but promotes ligand-independent dimerization.
- **Breast Cancer**: p.Asp811Asn (D811N) in the DFG motif, which confers constitutive kinase activity.
- **Colorectal Cancer**: p.Pro878Ser (P878S) in the kinase domain, which enhances kinase activity.

### 4.5 Clinical Differential Diagnosis

When a patient presents with suspected CSF1R-related disease, the differential diagnosis includes:

- **For ALSP**: Hereditary diffuse leukoencephalopathy with spheroids (HDLS, now considered the same entity), Nasu-Hakola disease (caused by TYROBP or TREM2 mutations), cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), multiple sclerosis, and frontotemporal dementia.
- **For CMML**: Chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of CSF1R Signaling

Several viruses have evolved mechanisms to exploit CSF1R signaling for immune evasion and viral propagation:

- **Human Cytomegalovirus (HCMV)**: HCMV encodes a viral chemokine receptor homolog, US28, which constitutively activates signaling pathways that cross-talk with CSF1R. HCMV infection of monocytes upregulates CSF1R expression, promoting monocyte survival and differentiation into macrophages, which serve as viral reservoirs. HCMV also induces the secretion of CSF1 from infected cells, creating a paracrine loop that sustains macrophage survival.
- **Human Immunodeficiency Virus (HIV)**: HIV-infected macrophages exhibit increased CSF1R expression. The HIV accessory protein Nef interacts with the CSF1R signaling pathway by activating VAV, a guanine nucleotide exchange factor that promotes actin remodeling. Nef also downregulates MHC-I, and CSF1R signaling enhances this effect by activating SRC family kinases. CSF1R signaling promotes the survival of HIV-infected macrophages, contributing to the establishment of long-lived viral reservoirs.
- **Epstein-Barr Virus (EBV)**: EBV latent membrane protein 2A (LMP2A) mimics B-cell receptor signaling and also activates CSF1R signaling in infected B cells. This cross-activation promotes B-cell survival and proliferation, contributing to EBV-associated lymphomas.

### 5.2 Bacterial Interactions

- **Mycobacterium tuberculosis**: M. tuberculosis infection of macrophages induces CSF1R expression via the TLR2/MyD88 pathway. CSF1R signaling promotes the survival of infected macrophages, allowing the bacteria to replicate intracellularly. Inhibition of CSF1R in a mouse model of tuberculosis reduced bacterial load and improved survival, suggesting that CSF1R is a host factor exploited by mycobacteria.
- **Salmonella enterica**: Salmonella infection upregulates CSF1R expression in macrophages. The bacterial effector protein SopB activates the PI3K/AKT pathway, which synergizes with CSF1R signaling to promote macrophage survival and bacterial dissemination.

### 5.3 Parasitic Interactions

- **Leishmania major**: Leishmania parasites infect macrophages and subvert CSF1R signaling to promote their survival. The parasite induces sustained CSF1R phosphorylation, leading to enhanced AKT activation and resistance to apoptosis. Blocking CSF1R signaling with a small-molecule inhibitor reduced parasite burden in infected mice.

### 5.4 Immune Evasion Mechanisms

CSF1R signaling is a major driver of the immunosuppressive tumor microenvironment. Tumor cells secrete CSF1, which recruits monocytes from the bone marrow and polarizes them into M2-like TAMs. These TAMs suppress anti-tumor immunity by:

- Secreting immunosuppressive cytokines (IL-10, TGF-β)
- Expressing immune checkpoint ligands (PD-L1, PD-L2)
- Depleting arginine and tryptophan via arginase-1 and IDO
- Recruiting regulatory T cells (Tregs) via CCL22

This makes CSF1R a critical node in tumor immune evasion, and its inhibition is a promising strategy to "re-educate" TAMs toward an anti-tumorigenic M1-like phenotype.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Therapeutics

**Pexidartinib (PLX3397)** is the only FDA-approved small-molecule inhibitor targeting CSF1R. It was approved in August 2019 for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to surgery. Pexidartinib is a multi-kinase inhibitor that targets CSF1R, KIT, and FLT3-ITD. It binds to the ATP-binding pocket of CSF1R with an IC50 of approximately 20 nM. The recommended dose is 400 mg orally once daily. Common adverse effects include fatigue, edema, and hepatotoxicity (elevated AST/ALT), which requires periodic liver function monitoring.

### 6.2 Investigational Small-Molecule Inhibitors

| **Drug** | **Target(s)** | **Development Phase** | **Indication** | **Mechanism** |
|---|---|---|---|---|
| PLX7486 | CSF1R, TRKA/B/C | Phase I | Solid tumors | ATP-competitive |
| ARRY-382 | CSF1R | Phase I/II | Advanced solid tumors | ATP-competitive |
| BLZ945 | CSF1R | Phase I/II | Glioblastoma, solid tumors | ATP-competitive, brain-penetrant |
| JNJ-40346527 (Edicotinib) | CSF1R | Phase II | Rheumatoid arthritis, ALSP | ATP-competitive |
| SNDX-6352 (Emactuzumab) | CSF1R (mAb) | Phase I/II | Solid tumors | Anti-CSF1R monoclonal antibody |
| Cabiralizumab (FPA008) | CSF1R (mAb) | Phase I/II | Pancreatic cancer, melanoma | Anti-CSF1R monoclonal antibody |
| IMC-CS4 (LY3022855) | CSF1R (mAb) | Phase I | Breast cancer | Anti-CSF1R monoclonal antibody |
| PD-0360324 | CSF1 (mAb) | Phase I | Solid tumors | Anti-CSF1 monoclonal antibody |

### 6.3 Monoclonal Antibodies

Monoclonal antibodies targeting CSF1R offer greater specificity than small-molecule inhibitors. Emactuzumab (RG7155) is a humanized IgG1 monoclonal antibody that binds to the D4 domain of CSF1R, blocking ligand binding and inducing receptor internalization. In a Phase I trial, emactuzumab reduced TAM infiltration in tumors and showed clinical activity in diffuse-type giant cell tumor (dtGCT). Cabiralizumab (FPA008) is another anti-CSF1R antibody that has been evaluated in combination with nivolumab (anti-PD-1) in pancreatic cancer. The combination showed a manageable safety profile and evidence of immune activation.

### 6.4 Combination Strategies

CSF1R inhibitors are most effective when combined with other therapeutic modalities:

- **Immune Checkpoint Inhibitors**: CSF1R inhibition reduces TAM-mediated immunosuppression, enhancing the efficacy of anti-PD-1/PD-L1 antibodies. Preclinical studies show synergistic anti-tumor activity in mouse models of melanoma and pancreatic cancer.
- **Chemotherapy**: CSF1R inhibition depletes TAMs that promote chemoresistance. Combination of pexidartinib with paclitaxel is being evaluated in ovarian cancer.
- **Radiotherapy**: CSF1R inhibition enhances the abscopal effect of radiation by promoting anti-tumor immunity.
- **CAR-T Cell Therapy**: CSF1R inhibition improves CAR-T cell infiltration and persistence in solid tumors by depleting immunosuppressive TAMs.

### 6.5 Pharmacogenomic Considerations

Polymorphisms in CSF1R may influence drug response and toxicity. The common variant rs10079250 (C>T) in the 3' UTR has been associated with altered CSF1R mRNA stability. Patients carrying the T allele may have lower CSF1R expression and reduced response to CSF1R inhibitors. Additionally, the HLA-A*02:01 allele has been associated with an increased risk of hepatotoxicity from pexidartinib, likely due to an immune-mediated mechanism.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 1436 | https://www.ncbi.nlm.nih.gov/gene/1436 |
| Ensembl | ENSG00000182578 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182578 |
| UniProt | P07333 | https://www.uniprot.org/uniprotkb/P07333 |
| RCSB PDB | 4R7I (ECD+CSF1), 3KRL (kinase) | https://www.rcsb.org/structure/4R7I |
| OMIM | 164770 (CSF1R), 221820 (ALSP) | https://www.omim.org/entry/164770 |
| ClinVar | CSF1R | https://www.ncbi.nlm.nih.gov/clinvar/?term=CSF1R |
| COSMIC | CSF1R | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CSF1R |
| STRING | CSF1R (P07333) | https://string-db.org/network/P07333 |
| BioGRID | 108346 | https://thebiogrid.org/108346 |
| Gene Ontology | GO:0004713 (RTK activity), GO:0007169 (transmembrane RTK signaling) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | R-HSA-1433557 (CSF1R signaling) | https://reactome.org/content/detail/R-HSA-1433557 |
| KEGG | hsa:1436 | https://www.genome.jp/dbget-bin/www_bget?hsa:1436 |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)


## References

1. Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. *Cold Spring Harbor Perspectives in Biology*. 2014;6(6):a021857. https://doi.org/10.1101/cshperspect.a021857

2. Rademakers R, Baker M, Nicholson AM, et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. *Nature Genetics*. 2011;44(2):200-205. https://doi.org/10.1038/ng.1027

3. Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. *The Lancet*. 2019;394(10197):478-487. https://doi.org/10.1016/S0140-6736(19)30764-0

4. Hume DA, MacDonald KPA. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. *Blood*. 2012;119(8):1810-1820. https://doi.org/10.1182/blood-2011-09-379214

5. Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Rüttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. *Journal for ImmunoTherapy of Cancer*. 2017;5:53. https://doi.org/10